Feasibility investigation of allogeneic endometrial regenerative cells
- PDF / 279,123 Bytes
- 7 Pages / 610 x 792 pts Page_size
- 65 Downloads / 229 Views
BioMed Central
Open Access
Research
Feasibility investigation of allogeneic endometrial regenerative cells Zhaohui Zhong1, Amit N Patel2, Thomas E Ichim*3, Neil H Riordan3, Hao Wang4, Wei-Ping Min4, Erik J Woods5, Michael Reid6, Eduardo Mansilla7, Gustavo H Marin7, Hugo Drago7, Michael P Murphy8 and Boris Minev9,10 Address: 1The Second Xiangya Hospital, Central South University, Changsha, PR China, 2Department of Cardiothoracic Surgery, University of Utah, Salt Lake City, USA, 3Medistem Inc, San Diego, USA, 4Department of Surgery, University of Western Ontario, Canada, 5General Biotechnology LLC, Indiana, USA, 6Body in Motion Consulting, Kitchener, Canada, 7Burns Hospital, Buenos Aires City, Argentina, 8Division of Vascular Surgery, Indiana University School of Medicine, Indiana, USA, 9Moores Cancer Center, University of California, San Diego and 10Division of Neurosurgery, University of California San Diego, San Diego, USA Email: Zhaohui Zhong - [email protected]; Amit N Patel - [email protected]; Thomas E Ichim* - [email protected]; Neil H Riordan - [email protected]; Hao Wang - [email protected]; Wei-Ping Min - [email protected]; Erik J Woods - [email protected]; Michael Reid - [email protected]; Eduardo Mansilla - [email protected]; Gustavo H Marin - [email protected]; Hugo Drago - [email protected]; Michael P Murphy - [email protected]; Boris Minev - [email protected] * Corresponding author
Published: 20 February 2009 Journal of Translational Medicine 2009, 7:15
doi:10.1186/1479-5876-7-15
Received: 15 January 2009 Accepted: 20 February 2009
This article is available from: http://www.translational-medicine.com/content/7/1/15 © 2009 Zhong et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract Endometrial Regenerative Cells (ERC) are a population of mesenchymal-like stem cells having pluripotent differentiation activity and ability to induce neoangiogenesis. In vitro and animal studies suggest ERC are immune privileged and in certain situations actively suppress ongoing immune responses. In this paper we describe the production of clinical grade ERC and initial safety experiences in 4 patients with multiple sclerosis treated intravenously and intrathecally. The case with the longest follow up, of more than one year, revealed no immunological reactions or treatment associated adverse effects. These preliminary data suggest feasibility of clinical ERC administration and support further studies with this novel stem cell type.
Introduction Endometrial Regenerative Cells (ERC) are a population of plastic adherent, mesenchymal-like stem cells that are possess in vitro pluripotency, and in vivo therapeutic activity in models of limb ischemia and infarcts [1-4]. Phenotypically ERC appear to share some markers with mesenchymal s
Data Loading...
